Physician profile
Mark D Marchand
NPI 1710959804
$406.51
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $86.49.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $150.08 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $54.39 | 2019 | |
| Merz North America, INC. | $46.22 | 2020 | |
| Csl Behring | $30.18 | 2019 | |
| Acorda Therapeutics, INC | $29.85 | 2019 | |
| Eisai INC. | $23.07 | 2019 | |
| Upsher-Smith Laboratories LLC | $21.06 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.06 | 2020 | |
| Ucb, INC. | $17.93 | 2019 | |
| Lundbeck LLC | $14.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Marchand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.